Phaseline

Targets › ITGB1

ITGB1 (Integrin beta-1): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 4; Neurology, Respiratory, Oncology; next expected readout Jul 2027.

Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. (UniProt, P05556)

Open in Phaseline: the race on ITGB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The Cleveland ClinicNatalizumab
Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor
ITGA4, ITGB7, ITGB1Phase 4Multiple Sclerosis, Relapsing-RemittingJul 2027
Queen Mary University of LondonNatalizumab
Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor
ITGA4, ITGB7, ITGB1Phase 2Multiple SclerosisOct 2027
University of Michigan Rogel Cancer CenterNatalizumab
Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor
ITGA4, ITGB7, ITGB1Phase 2Recurrent Diffuse Large B-Cell LymphomaMay 2028
Oorja BioORJ-001
β1 integrin agonist peptide
ITGB1Phase 2Idiopathic Pulmonary FibrosisJan 2029

Conditions

Idiopathic Pulmonary Fibrosis (1) Recurrent Diffuse Large B-Cell Lymphoma (1) Multiple Sclerosis (1) Multiple Sclerosis, Relapsing-Remitting (1)

Modalities

mixed (2), small molecule (1), antibody (1)

Companies

Oorja Bio (1) University of Michigan Rogel Cancer Center (1) Queen Mary University of London (1) The Cleveland Clinic (1)

Related targets

ITGA4 (3) ITGB7 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.